Table 3.
Risk of mantle cell lymphoma associated with a history of hematological malignancy in a first-degree relative, overall and by sex of the patient and the relative*
| Total | P | Females | P | Males | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First-degree family history | Controls†, No. (%) | Cases†, No. (%) | OR (95% CI) | Controls†, No. (%) | Cases†, No. (%) | OR (95% CI) | Controls†, No. (%) | Cases†, No. (%) | OR (95% CI) | P | ||
| Any hematologic malignancy | ||||||||||||
| No | 8519 (86.2) | 298 (77.0) | 1.00 (referent) | <.001 | 4039 (84.8) | 84 (79.2) | 1.00 (referent) | .194 | 4081 (86.2) | 214 (76.2) | 1.00 (referent) | <.001 |
| Yes | 492 (5.0) | 39 (10.1) | 1.99 (1.39 to 2.84) | 267 (5.6) | 10 (9.4) | 1.61 (0.82 to 3.19) | 216 (4.6) | 29 (10.3) | 2.21 (1.44 to 3.38) | |||
| Any hematologic malignancy, male relative | ||||||||||||
| No | 7940 (88.0) | 283 (79.7) | 1.00 (referent) | .001 | 3907 (87.1) | 84 (82.4) | 1.00 (referent) | .164 | 3696 (88.1) | 199 (78.7) | 1.00 (referent) | .004 |
| Yes | 230 (2.5) | 22 (6.2) | 2.33 (1.46 to 3.72) | 122 (2.7) | 6 (5.9) | 1.96 (0.82 to 4.66) | 104 (2.5) | 16 (6.3) | 2.48 (1.41 to 4.34) | |||
| Any hematologic malignancy, female relative | ||||||||||||
| No | 7936 (87.9) | 288 (81.1) | 1.00 (referent) | .064 | 3903 (87.0) | 86 (84.3) | 1.00 (referent) | .571 | 3695 (88.1) | 202 (79.8) | 1.00 (referent) | .051 |
| Yes | 234 (2.6) | 17 (4.8) | 1.69 (1.00 to 2.84) | 126 (2.8) | 4 (3.9) | 1.37 (0.49 to 3.84) | 105 (2.5) | 13 (5.1) | 1.92 (1.04 to 3.53) | |||
| NHL† | ||||||||||||
| No | 8085 (88.2) | 296 (81.8) | 1.00 (referent) | .024 | 3913 (87.2) | 88 (86.3) | 1.00 (referent) | .65 | 3767 (88.5) | 208 (80.0) | 1.00 (referent) | .005 |
| Yes | 205 (2.2) | 16 (4.4) | 1.95 (1.14 to 3.34) | 116 (2.6) | 2 (2.0) | 0.73 (0.18 to 3.04) | 86 (2.0) | 14 (5.4) | 2.58 (1.41 to 4.71) | |||
| NHL, male relative | ||||||||||||
| No | 8077 (89.5) | 295 (83.1) | 1.00 (referent) | .009 | 3977 (88.6) | 88 (86.3) | 1.00 (referent) | .536 | 3137 (87.9) | 176 (79.3) | 1.00 (referent) | .013 |
| Yes | 93 (1.0) | 10 (2.8) | 2.78 (1.40 to 5.52) | 52 (1.2) | 2 (2.0) | 1.64 (0.38 to 7.01) | 40 (1.1) | 8 (3.6) | 3.11 (1.40 to 6.93) | |||
| NHL, female relative | ||||||||||||
| No | 8061 (89.3) | 301 (84.8) | 1.00 (referent) | .775 | 3966 (88.4) | 90 (88.2) | 1.00 (referent) | .09 | 3754 (89.5) | 211 (83.4) | 1.00 (referent) | .607 |
| Yes | 109 (1.2) | 4 (1.1) | 0.87 (0.31 to 2.39) | 63 (1.4) | 0 (0.0) | — | 46 (1.1) | 4 (1.6) | 1.33 (0.47 to 3.81) | |||
| Leukemia†,‡ | ||||||||||||
| No | 7930 (87.9) | 286 (80.6) | 1.00 (referent) | .012 | 3903 (87.0) | 84 (82.4) | 1.00 (referent) | .116 | 3692 (88.0) | 202 (79.8) | 1.00 (referent) | .036 |
| Yes | 240 (2.6) | 19 (5.1) | 2.01 (1.10 to 3.68) | 126 (2.8) | 6 (5.9) | 2.14 (0.90 to 5.09) | 108 (2.6) | 13 (5.1) | 2.01 (1.10 to 3.68) | |||
| Leukemia, male relative | ||||||||||||
| No | 3743 (89.2) | 210 (83.0) | 1.00 (referent) | .498 | 3958 (88.2) | 87 (85.3) | 1.00 (referent) | .398 | 3743 (89.2) | 210 (83.0) | 1.00 (referent) | .498 |
| Yes | 131 (1.4) | 8 (2.0) | 1.40 (0.55 to 3.59) | 71 (1.6) | 3 (2.9) | 1.75 (0.53 to 5.82) | 57 (1.4) | 5 (2.0) | 1.40 (0.55 to 3.59) | |||
| Leukemia, female relative | ||||||||||||
| No | 3750 (89.4) | 207 (81.8) | 1.00 (referent) | .026 | 3303 (86.7) | 76 (83.5) | 1.00 (referent) | .128 | 3750 (89.4) | 207 (81.8) | 1.00 (referent) | .026 |
| Yes | 103 (1.2) | 11 (3.2) | 2.66 (1.22 to 5.81) | 50 (1.3). | 3 (3.3) | 2.92 (0.87 to 9.80) | 50 (1.2) | 8 (3.2) | 2.66 (1.22 to 5.81) | |||
* Odds ratio (OR) and 95% confidence interval (CI) adjusted for age, sex, race, and study. NHL = non-Hodgkin lymphoma.
† The counts do not add up to the total number of cases and controls due to data missing by design or report. Also, male and female counts do not always add up to the total as all studies did not contribute to every analysis.
‡ Based on International Statistical Classification of Diseases and Related Health Problems (ICD)- 9 and ICD10 classification.